Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24898182 | 0.91 | HPGD (0.51) | HPGDHTTSMN1; SMN2USP2TP53 | |
| SCHEMBL24575950 | 0.89 | HPGD (0.72) | HPGDHTTSMN1; SMN2USP2TP53 | |
| SCHEMBL14559553 | 0.84 | HPGD (0.62) | HPGDHTTSMN1; SMN2USP2TP53 | |
| SCHEMBL1101625 | 0.81 | SMN1; SMN2 (0.64) | HPGDHTTSMN1; SMN2USP2TP53 | |
| SCHEMBL12409354 | 0.81 | SMN1; SMN2 (0.64) | HPGDHTTSMN1; SMN2USP2TP53 | |
| SCHEMBL12409226 | 0.81 | SMN1; SMN2 (0.64) | HPGDHTTSMN1; SMN2USP2TP53 | |
| SCHEMBL2864022 | 0.79 | SMN1; SMN2 (0.66) | HPGDHTTSMN1; SMN2USP2TP53 | |
| SCHEMBL4420466 | 0.79 | SMN1; SMN2 (0.66) | HPGDHTTSMN1; SMN2USP2TP53 | |
| SCHEMBL6061649 | 0.79 | SMN1; SMN2 (0.66) | HPGDHTTSMN1; SMN2USP2TP53 | |
| SCHEMBL4429350 | 0.79 | SMN1; SMN2 (0.66) | HPGDHTTSMN1; SMN2USP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2014-09-18 | — | — | US | disclosed |
| WO-2011142359-A1 | SPIRO COMPOUND AND DRUG FOR ACTIVATING ADIPONECTIN RECEPTOR | 日産化学工業株式会社 (JP) | 2011-11-17 | — | — | WO | disclosed |
| WO-2006101454-A1 | BENZOTHIOPHENE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD (SG) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | HPGD 332/4885HTT 4596/4885SMN1; SMN2 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.